As Your Swiss and Croatian ATMP Market Access Expert, Sur Access is uniquely positioned to guide Advanced Therapy Medicinal Products (ATMPs) – from gene to cell therapies – through the complex journey from groundbreaking science to widespread patient access. We understand that the true value of innovation isn't just in its discovery, but in its ability to reach those who need it most.

Our mission is to bridge the critical gap between profound scientific achievement and the intricate reimbursement landscape. We partner with you to translate your deep scientific and business understanding into sustainable market access and impactful commercial success, particularly within the challenging Swiss, Croatian, and broader European contexts. We facilitate consensus, ensuring both industry and HTA bodies find win-win solutions that prioritize patient access.

Led by Dr. Sanja Fitzgerald, Sur Access offers a distinct advantage: a market access strategy built on a rare and powerful blend of scientific depth, commercial acumen, and specialized HTA expertise. My journey to market access is unconventional, providing you with a unique perspective:

• 12.5 Years in Biotech Innovation (Firmenich): I bring over a decade of hands-on experience at the heart of biotech R&D and business development.
• Computational Chemistry & Discovery: My background as a Computational Chemist and R&D Scientist involved direct work in new molecule discovery and in silico modeling. This equips me with an intrinsic understanding of the science behind complex therapies – how they're discovered, how they work at a molecular level, and their inherent innovation.
• Innovation & Business Leadership: Progressing into roles as Account Manager and Innovation Director, I gained firsthand experience in commercial strategy, product value proposition, and driving business growth within a highly innovative industry.
• HTAi Rare Disease Insight: As a Technical Officer and the right hand of the HTAi Rare Disease Interest Group (RDIG) Chair, I am deeply connected to the latest global developments and evolving methodologies in HTA for rare diseases. This unique position offers unparalleled foresight into emerging payer expectations and value frameworks for ATMPs (https://www.impact-hta.eu/work-package-10).
• Specialized ATMP Market Access Expertise (since 2021): My focused transition into market access in 2021 has allowed me to apply this rich scientific and business foundation directly to the nuances of reimbursement. I understand HTA bodies and frameworks from the inside, enabling me to build strategies that genuinely resonate with payers.
• Dual National & Local Mastery: As a Swiss and Croatian national, I possess an intimate, 'inside-out' understanding of the local rules, legislation, and negotiation dynamics in Switzerland and Croatia. This direct experience informs every strategic recommendation, from global market access planning to local dossier submission.

Driving Predictable Value for Your ATMP

This unique vantage point empowers Sur Access to deliver precise, effective market access strategies, especially for ATMPs:

• Science-Informed Value Proposition: I excel at translating complex scientific innovation into a compelling value story that resonates with both clinicians and payers, leveraging my R&D background.
• Strategic HTA & Payer Negotiations: Navigating the most challenging reimbursement environments, from the intricacies of German AMNOG (check our Portfolio) to the specific dynamics of Switzerland, Croatia, the U.S., and key European markets.
• Innovative Pricing Models: Designing robust value-based pricing strategies and pioneering Managed Entry Agreements (MEAs) that align with payer expectations while maximizing product value.
• Holistic Evidence Generation: Guiding clinical development and real-world evidence strategies to proactively meet future HTA demands.
• Realistic Forecasting & Risk Mitigation: Providing forecasts grounded in a deep understanding of scientific potential, commercial realities, and payer willingness-to-pay, avoiding the pitfalls of 'analogue pricing' and de-risking your launch.

Your Dedicated Partner for ATMP Success

In the high-stakes world of Advanced Therapies, Sur Access offers a distinct advantage: a deep understanding of your product's science, its business potential, and the market access pathways required for success.

Our Commitment: To ensure your groundbreaking ATMPs reach patients widely and sustainably, by bridging the critical gap between innovation and market realization.